CAN508

Name: CAN508
Brand: MedChemExpress
SKU: HY-100429
Rating: 4.5 (1 reviews)

製品番号: HY-100429 純度: 99.71%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC₅₀ of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAN508 構造式

CAS 番号 : 140651-18-9

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 93	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 93	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$85	在庫あり	Estimated Time of Arrival: December 31
10 mg	$128	在庫あり	Estimated Time of Arrival: December 31
25 mg	$256	在庫あり	Estimated Time of Arrival: December 31
50 mg	$385	在庫あり	Estimated Time of Arrival: December 31
100 mg		お問い合わせ
200 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

顧客検証

•Universidade de Lisboa. 2021 Dec 21.

CDK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target^[1]

CDK9/cyclinT1

0.35 μM (IC₅₀)

CDK2/cyclinE

20 μM (IC₅₀)

cdk2/cyclin A

69 μM (IC₅₀)

Cdk4/cyclin D1

13.5 μM (IC₅₀)

CDK7/cyclin H

26 μM (IC₅₀)

Cdk1/cyclin B

44 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	GI₅₀	26.2 μM Compound: CAN508	Cytotoxicity against human 786-0 cells Cytotoxicity against human 786-0 cells	[PMID: 21777997]
A498	GI₅₀	18.2 μM Compound: CAN508	Cytotoxicity against human A498 cells Cytotoxicity against human A498 cells	[PMID: 21777997]
A549	GI₅₀	22.5 μM Compound: CAN508	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 21777997]
ACHN	GI₅₀	15.6 μM Compound: CAN508	Cytotoxicity against human ACHN cells Cytotoxicity against human ACHN cells	[PMID: 21777997]
BT-549	GI₅₀	14 μM Compound: CAN508	Cytotoxicity against human BT549 cells Cytotoxicity against human BT549 cells	[PMID: 21777997]
CAKI-1	GI₅₀	14.8 μM Compound: CAN508	Cytotoxicity against human Caki1 cells Cytotoxicity against human Caki1 cells	[PMID: 21777997]
CCRF-CEM	GI₅₀	20 μM Compound: CAN508	Cytotoxicity against human CCRF-CEM cells Cytotoxicity against human CCRF-CEM cells	[PMID: 21777997]
COLO 205	GI₅₀	18.9 μM Compound: CAN508	Cytotoxicity against human COLO205 cells Cytotoxicity against human COLO205 cells	[PMID: 21777997]
DU-145	GI₅₀	17 μM Compound: CAN508	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 21777997]
EKVX	GI₅₀	22 μM Compound: CAN508	Cytotoxicity against human EKVX cells Cytotoxicity against human EKVX cells	[PMID: 21777997]
G-361	IC₅₀	64 μM Compound: 31b, (CAN508)	Antiproliferative activity against G361 cell line Antiproliferative activity against G361 cell line	[PMID: 17064068]
HCC 2998	GI₅₀	29.4 μM Compound: CAN508	Cytotoxicity against human HCC2998 cells Cytotoxicity against human HCC2998 cells	[PMID: 21777997]
HCT-116	GI₅₀	18.9 μM Compound: CAN508	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 21777997]
HCT-15	GI₅₀	24.2 μM Compound: CAN508	Cytotoxicity against human HCT15 cells Cytotoxicity against human HCT15 cells	[PMID: 21777997]
HL-60(TB)	GI₅₀	6.4 μM Compound: CAN508	Cytotoxicity against human HL-60(TB) cells Cytotoxicity against human HL-60(TB) cells	[PMID: 21777997]
HMEC-1	IC₅₀	20 μM Compound: CAN508	Inhibition of RNA synthesis in human HMEC1 cells assessed as decrease in [3H] Uridine incorporation after 2 hrs by scintillation counting Inhibition of RNA synthesis in human HMEC1 cells assessed as decrease in [3H] Uridine incorporation after 2 hrs by scintillation counting	[PMID: 21777997]
HOP-62	GI₅₀	31.8 μM Compound: CAN508	Cytotoxicity against human HOP62 cells Cytotoxicity against human HOP62 cells	[PMID: 21777997]
HOP-92	GI₅₀	18.2 μM Compound: CAN508	Cytotoxicity against human HOP92 cells Cytotoxicity against human HOP92 cells	[PMID: 21777997]
HOS	IC₅₀	49 μM Compound: 31b, (CAN508)	Antiproliferative activity against HOS cell line Antiproliferative activity against HOS cell line	[PMID: 17064068]
HT-29	GI₅₀	29.7 μM Compound: CAN508	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 21777997]
Hs-578T	GI₅₀	21.8 μM Compound: CAN508	Cytotoxicity against human Hs 578T cells Cytotoxicity against human Hs 578T cells	[PMID: 21777997]
IGROV-1	GI₅₀	20.6 μM Compound: CAN508	Cytotoxicity against human IGROV1 cells Cytotoxicity against human IGROV1 cells	[PMID: 21777997]
K562	GI₅₀	9.2 μM Compound: CAN508	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 21777997]
K562	IC₅₀	33 μM Compound: IIIa, CAN508	Cytotoxicity against human K562 cells after 72 hrs by calcein AM staining-based fluorescence assay Cytotoxicity against human K562 cells after 72 hrs by calcein AM staining-based fluorescence assay	[PMID: 25835357]
K562	IC₅₀	62 μM Compound: 31b, (CAN508)	Antiproliferative activity against K562 cell line Antiproliferative activity against K562 cell line	[PMID: 17064068]
KM12	GI₅₀	17.1 μM Compound: CAN508	Cytotoxicity against human KM12 cells Cytotoxicity against human KM12 cells	[PMID: 21777997]
LOX IMVI	GI₅₀	4.1 μM Compound: CAN508	Cytotoxicity against human LOXIMVI cells Cytotoxicity against human LOXIMVI cells	[PMID: 21777997]
M14	GI₅₀	15.9 μM Compound: CAN508	Cytotoxicity against human M14 cells Cytotoxicity against human M14 cells	[PMID: 21777997]
MCF7	GI₅₀	23.5 μM Compound: CAN508	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 21777997]
MCF7	IC₅₀	15 μM Compound: CAN508	Inhibition of RNA synthesis in human MCF7 cells assessed as decrease in [3H] Uridine incorporation after 2 hrs by scintillation counting Inhibition of RNA synthesis in human MCF7 cells assessed as decrease in [3H] Uridine incorporation after 2 hrs by scintillation counting	[PMID: 21777997]
MCF7	IC₅₀	33 μM Compound: 31b, (CAN508)	Antiproliferative activity against MCF7 cell line Antiproliferative activity against MCF7 cell line	[PMID: 17064068]
MCF7	IC₅₀	62 μM Compound: IIIa, CAN508	Cytotoxicity against human MCF7 cells after 72 hrs by calcein AM staining-based fluorescence assay Cytotoxicity against human MCF7 cells after 72 hrs by calcein AM staining-based fluorescence assay	[PMID: 25835357]
MDA-MB-231	GI₅₀	16.7 μM Compound: CAN508	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 21777997]
MDA-MB-435	GI₅₀	17.1 μM Compound: CAN508	Cytotoxicity against human MDA-MB-435 cells Cytotoxicity against human MDA-MB-435 cells	[PMID: 21777997]
MOLT-4	GI₅₀	13.5 μM Compound: CAN508	Cytotoxicity against human MOLT4 cells Cytotoxicity against human MOLT4 cells	[PMID: 21777997]
Malme-3M	GI₅₀	24.5 μM Compound: CAN508	Cytotoxicity against human MALME-3M cells Cytotoxicity against human MALME-3M cells	[PMID: 21777997]
NCI-H226	GI₅₀	17.7 μM Compound: CAN508	Cytotoxicity against human NCI-H226 cells Cytotoxicity against human NCI-H226 cells	[PMID: 21777997]
NCI-H23	GI₅₀	19.1 μM Compound: CAN508	Cytotoxicity against human NCI-H23 cells Cytotoxicity against human NCI-H23 cells	[PMID: 21777997]
NCI-H322M	GI₅₀	25.1 μM Compound: CAN508	Cytotoxicity against human NCI-H322M cells Cytotoxicity against human NCI-H322M cells	[PMID: 21777997]
NCI-H460	GI₅₀	25.1 μM Compound: CAN508	Cytotoxicity against human NCI-H460 cells Cytotoxicity against human NCI-H460 cells	[PMID: 21777997]
NCI-H522	GI₅₀	24.3 μM Compound: CAN508	Cytotoxicity against human NCI-H522 cells Cytotoxicity against human NCI-H522 cells	[PMID: 21777997]
NCI/ADR-RES	GI₅₀	22.5 μM Compound: CAN508	Cytotoxicity against human NCI/ADR-RES cells Cytotoxicity against human NCI/ADR-RES cells	[PMID: 21777997]
OVCAR-3	GI₅₀	22.8 μM Compound: CAN508	Cytotoxicity against human OVCAR3 cells Cytotoxicity against human OVCAR3 cells	[PMID: 21777997]
OVCAR-4	GI₅₀	19 μM Compound: CAN508	Cytotoxicity against human OVCAR4 cells Cytotoxicity against human OVCAR4 cells	[PMID: 21777997]
OVCAR-5	GI₅₀	23.5 μM Compound: CAN508	Cytotoxicity against human OVCAR5 cells Cytotoxicity against human OVCAR5 cells	[PMID: 21777997]
OVCAR-8	GI₅₀	18 μM Compound: CAN508	Cytotoxicity against human OVCAR8 cells Cytotoxicity against human OVCAR8 cells	[PMID: 21777997]
PC-3	GI₅₀	20.3 μM Compound: CAN508	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 21777997]
RPMI-8226	GI₅₀	14.4 μM Compound: CAN508	Cytotoxicity against human RPMI8226 cells Cytotoxicity against human RPMI8226 cells	[PMID: 21777997]
RPMI-8226	IC₅₀	24.9 μM Compound: IIIa, CAN508	Cytotoxicity against human RPMI8226 cells after 72 hrs by calcein AM staining-based fluorescence assay Cytotoxicity against human RPMI8226 cells after 72 hrs by calcein AM staining-based fluorescence assay	[PMID: 25835357]
RXF 393	GI₅₀	18.4 μM Compound: CAN508	Cytotoxicity against human RXF393 cells Cytotoxicity against human RXF393 cells	[PMID: 21777997]
SF-268	GI₅₀	20.6 μM Compound: CAN508	Cytotoxicity against human SF268 cells Cytotoxicity against human SF268 cells	[PMID: 21777997]
SF-295	GI₅₀	23.3 μM Compound: CAN508	Cytotoxicity against human SF295 cells Cytotoxicity against human SF295 cells	[PMID: 21777997]
SF-539	GI₅₀	13.2 μM Compound: CAN508	Cytotoxicity against human SF539 cells Cytotoxicity against human SF539 cells	[PMID: 21777997]
SK-MEL-2	GI₅₀	14.4 μM Compound: CAN508	Cytotoxicity against human SK-MEL-2 cells Cytotoxicity against human SK-MEL-2 cells	[PMID: 21777997]
SK-MEL-28	GI₅₀	22.1 μM Compound: CAN508	Cytotoxicity against human SK-MEL-28 cells Cytotoxicity against human SK-MEL-28 cells	[PMID: 21777997]
SK-MEL-5	GI₅₀	13.9 μM Compound: CAN508	Cytotoxicity against human SK-MEL-5 cells Cytotoxicity against human SK-MEL-5 cells	[PMID: 21777997]
SK-OV-3	GI₅₀	49.2 μM Compound: CAN508	Cytotoxicity against human SKOV3 cells Cytotoxicity against human SKOV3 cells	[PMID: 21777997]
SN12C	GI₅₀	23.3 μM Compound: CAN508	Cytotoxicity against human SN12C cells Cytotoxicity against human SN12C cells	[PMID: 21777997]
SNB-19	GI₅₀	29.9 μM Compound: CAN508	Cytotoxicity against human SNB19 cells Cytotoxicity against human SNB19 cells	[PMID: 21777997]
SNB-75	GI₅₀	18.5 μM Compound: CAN508	Cytotoxicity against human SNB75 cells Cytotoxicity against human SNB75 cells	[PMID: 21777997]
SR	GI₅₀	10.3 μM Compound: CAN508	Cytotoxicity against human SR cells Cytotoxicity against human SR cells	[PMID: 21777997]
SW-620	GI₅₀	26.3 μM Compound: CAN508	Cytotoxicity against human SW620 cells Cytotoxicity against human SW620 cells	[PMID: 21777997]
Sf9	IC₅₀	0.35 μM Compound: IIIa, CAN508	Inhibition of CDK9/cyclin T1 (unknown origin) expressed in baculovirus infected Sf9 cells Inhibition of CDK9/cyclin T1 (unknown origin) expressed in baculovirus infected Sf9 cells	[PMID: 25835357]
Sf9	IC₅₀	13.5 μM Compound: IIIa, CAN508	Inhibition of CDK4/cyclin D1 (unknown origin) expressed in baculovirus infected Sf9 cells Inhibition of CDK4/cyclin D1 (unknown origin) expressed in baculovirus infected Sf9 cells	[PMID: 25835357]
Sf9	IC₅₀	20 μM Compound: IIIa, CAN508	Inhibition of CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf9 cells Inhibition of CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf9 cells	[PMID: 25835357]
Sf9	IC₅₀	26 μM Compound: IIIa, CAN508	Inhibition of CDK7/cyclin H (unknown origin) expressed in baculovirus infected Sf9 cells Inhibition of CDK7/cyclin H (unknown origin) expressed in baculovirus infected Sf9 cells	[PMID: 25835357]
Sf9	IC₅₀	44 μM Compound: IIIa, CAN508	Inhibition of CDK1/cyclin B (unknown origin) expressed in baculovirus infected Sf9 cells Inhibition of CDK1/cyclin B (unknown origin) expressed in baculovirus infected Sf9 cells	[PMID: 25835357]
T47D	GI₅₀	14.2 μM Compound: CAN508	Cytotoxicity against human T47D cells Cytotoxicity against human T47D cells	[PMID: 21777997]
TK-10	GI₅₀	25.6 μM Compound: CAN508	Cytotoxicity against human TK10 cells Cytotoxicity against human TK10 cells	[PMID: 21777997]
U-251	GI₅₀	21.2 μM Compound: CAN508	Cytotoxicity against human U251 cells Cytotoxicity against human U251 cells	[PMID: 21777997]
UACC-257	GI₅₀	24.4 μM Compound: CAN508	Cytotoxicity against human UACC257 cells Cytotoxicity against human UACC257 cells	[PMID: 21777997]
UACC-62	GI₅₀	11 μM Compound: CAN508	Cytotoxicity against human UACC62 cells Cytotoxicity against human UACC62 cells	[PMID: 21777997]
UO-31	GI₅₀	13.7 μM Compound: CAN508	Cytotoxicity against human UO31 cells Cytotoxicity against human UO31 cells	[PMID: 21777997]

体外実験

CAN508 reduces the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays^[1].
CAN508 (20-40 μM; 72 hours) significantly reduces cell proliferation in a dose dependent manner in all three esophageal adenocarcinoma cell lines (SKGT4, OE33 and FLO-1 cells) with IC₅₀s ranging from 34.99 to 91.09 μM^[2].
CAN508 (40 μM; 72 hours) increases apoptosis in all three esophageal adenocarcinoma cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	SKGT4, OE33 and FLO-1 cells
Concentration:	40 μM
Incubation Time:	72 hours
Result:	Increased apoptosis by 2 fold in all three esophageal adenocarcinoma cells compared to untreated controls.

体内実験

CAN508 (60 mg/kg; i.p.; daily for 10 days) has antitumor effects in esophageal adenocarcinoma xenografts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4 weeks-old female nude mice (esophageal adenocarcinoma xenografts)^[1]
Dosage:	60 mg/kg
Administration:	I.p.; daily for 10 days
Result:	Caused reduction of tumor growth starting from post-treatment day three with 50.83% reduction.

分子量

218.22

分子式

C₉H₁₀N₆O

CAS 番号

140651-18-9

Appearance

Solid

Color

Light yellow to yellow

SMILES

OC1=CC=C(/N=N/C2=C(N)NN=C2N)C=C1

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 250 mg/mL (1145.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.5825 mL	22.9127 mL	45.8253 mL
5 mM	0.9165 mL	4.5825 mL	9.1651 mL
10 mM	0.4583 mL	2.2913 mL	4.5825 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (9.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.71%

Select Batch:

データシート (276 KB) SDS (252 KB)

COA (248 KB) HNMR (244 KB) LCMS (104 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Krystof V, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006;49(22):6500-6509. [Content Brief]

[2]. Tong Z, et al. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017;8(17):28696-28710. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.5825 mL	22.9127 mL	45.8253 mL	114.5633 mL
	5 mM	0.9165 mL	4.5825 mL	9.1651 mL	22.9127 mL
	10 mM	0.4583 mL	2.2913 mL	4.5825 mL	11.4563 mL
	15 mM	0.3055 mL	1.5275 mL	3.0550 mL	7.6376 mL
	20 mM	0.2291 mL	1.1456 mL	2.2913 mL	5.7282 mL
	25 mM	0.1833 mL	0.9165 mL	1.8330 mL	4.5825 mL
	30 mM	0.1528 mL	0.7638 mL	1.5275 mL	3.8188 mL
	40 mM	0.1146 mL	0.5728 mL	1.1456 mL	2.8641 mL
	50 mM	0.0917 mL	0.4583 mL	0.9165 mL	2.2913 mL
	60 mM	0.0764 mL	0.3819 mL	0.7638 mL	1.9094 mL
	80 mM	0.0573 mL	0.2864 mL	0.5728 mL	1.4320 mL
	100 mM	0.0458 mL	0.2291 mL	0.4583 mL	1.1456 mL

CAN508 Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CAN508140651-18-9CAN 508CAN-508CDKCyclin dependent kinaseHT-29cellsesophagealadenocarcinomaATP-competitiveInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

CAN508

カスタマーレビュー

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

CDK アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

CAN508 Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

CAN508

カスタマーレビュー

CAN508 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

CDK アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

CAN508 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

CAN508 Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report